Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Jacobs (JEC) Awarded EPCM Contract By Aerie Pharmaceuticals

Published 09/19/2017, 10:43 PM
Updated 07/09/2023, 06:31 AM

Jacobs Engineering Group Inc. (NYSE:JEC) recently secured an engineering, procurement and construction management services (EPCM) contract from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) , for an undisclosed amount.

Over the last month, shares of Jacobs yielded a return of 14.7%, outperforming 11.6% growth recorded by the industry.



This Zacks Rank #3 (Hold) company is poised to grow on the back of diligent business contracts and sound restructuring initiatives. Notably, Jacobs also signed an agreement (on Aug 7, 2017) to acquire CH2M HILL Companies Ltd., which is in sync with its efforts to become a $15-billion global solutions provider over the long run.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Inside Story

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company, focused on the development, discovery and commercialization of premium first-in-class therapies, for treating patients with glaucoma and other eye diseases. The company’s new pharmaceutical manufacturing plant will be located in the Industrial Development Authority’s technology building in Athlone, Republic of Ireland. This facility is being built to commercially process sterile ophthalmic solutions going forward. These solutions will also be sterile filtered, compounded and filled aseptically in the plant.

Leveraging the EPCM expertise for fill-finish facilities, Jacobs will support the design and construction activities of Aerie Pharmaceuticals’ Ireland based pharmaceutical manufacturing plant. Notably, Jacobs will provide further support to Aerie Pharmaceuticals for discovering premium therapies for the treatment of different types of eye diseases going forward.

Jacobs quotes competitive prices for its contracts and ensures that the number of contract receipts increases over time. In the last few months, the company has won a number of contracts from renowned institutions and public-sector agencies like the Chevron Corporation (NYSE:CVX) , Huntington Ingalls

Industries, Inc. (NYSE:HII) , National Aeronautics and Space Administration, and the U.S. Army. Notably, higher transportation spending of the government authorities of Australia, the U.K. and the United States has largely increased Jacobs’ contract winning opportunities in the near term.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Huntington Ingalls Industries, Inc. (HII): Free Stock Analysis Report

Jacobs Engineering Group Inc. (JEC): Free Stock Analysis Report

Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report

Chevron Corporation (CVX): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.